Advertisement


Sara A. Hurvitz, MD, FACP, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-03

ASCO 2026

Advertisement

Sara A. Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-03 trial. The study compared sacituzumab govitecan vs chemotherapy in patients with previously untreated metastatic triple-negative breast cancer (Abstract 1001).



Related Videos

Lung Cancer

Sanjay Popat, PhD, FRCP, on RET Fusion-Positive NSCLC: First-Line Pralsetinib

Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhibitor pralsetinib as first-line therapy for patients with RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC) (Abstract 8504).

Lung Cancer

Lauren Averett Byers, MD, on ABBV-706 in Relapsed or Refractory SCLC

Lauren Averett Byers, MD, of The University of Texas MD Anderson Cancer Center, describes data on ABBV-706—an investigational antibody-drug conjugate targeting SEZ6—alone or in combination with the anti–PD-1 monoclonal antibody budigalimab in patients with relapsed or refractory small cell lung cancer (SCLC) (Abstract 8008). 

Lymphoma

Manali Kamdar, MD, on Rapid Oral Abstract Highlights: Three Emerging Trends in Lymphoma Care

Manali Kamdar, MD, of the University of Colorado, discusses a rapid oral abstract session that highlighted three trends in the field of lymphomas: improving outcomes in frontline diffuse large B-cell lymphoma, continued development of cellular therapies, and expanding molecular profiling. 

Breast Cancer

Jame Abraham, MD, FACP, on Update on the DESTINY-Breast05 Trial

Jame Abraham, MD, FACP, of Cleveland Clinic, provides an update on the DESTINY-Breast05 trial, which is an ongoing phase III trial investigating postneoadjuvant trastuzumab deruxtecan (T-DXd) as compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with residual invasive disease and node-positive disease at surgery or inoperable disease at diagnosis. Dr. Abraham makes special note of rates of interstitial lung disease seen in the trial and methods of management.

Skin Cancer

Marlana M. Orloff, MD, on Metastatic Uveal Melanoma: First-Line Therapy for HLA-A2–Negative Disease

Marlana M. Orloff, MD, of Thomas Jefferson University Hospital, reviews primary results from the OptimUM-02 trial, which investigated the doublet of darovasertib plus crizotinib vs investgator’s choice for first-line therapy among patients with HLA-A2–negative metastatic uveal melanoma (Abstract LBA9503). 

Advertisement

Advertisement




Advertisement